KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBIT: 2018-2024

Historic EBIT for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $8.7 million.

  • Castle Biosciences' EBIT fell 233.96% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 3265.41%. This contributed to the annual value of $8.7 million for FY2024, which is 112.75% up from last year.
  • Latest data reveals that Castle Biosciences reported EBIT of $8.7 million as of FY2024, which was up 112.75% from -$68.0 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' EBIT registered a high of $8.7 million during FY2024, and its lowest value of -$72.9 million during FY2022.
  • In the last 3 years, Castle Biosciences' EBIT had a median value of -$68.0 million in 2023 and averaged -$44.1 million.
  • Its EBIT has fluctuated over the past 5 years, first slumped by 512.64% in 2021, then soared by 112.75% in 2024.
  • Yearly analysis of 5 years shows Castle Biosciences' EBIT stood at -$6.5 million in 2020, then slumped by 512.64% to -$40.1 million in 2021, then tumbled by 81.78% to -$72.9 million in 2022, then increased by 6.70% to -$68.0 million in 2023, then soared by 112.75% to $8.7 million in 2024.